US FDA Outlines Internal ANDA Refuse-To-Receive Policy
Manual of Policies and Procedures document should provide more help to sponsors on what items must be in an ANDA for it to be reviewed.
You may also be interested in...
Agency made few of industry's requested changes regarding when it would refuse to receive generic applications, but the absence of comments from several big generics companies indicates some level of satisfaction.
FDA's generic office director notes a jump in year-end submissions – and a jump in refuse-to-receive actions.
Teva official calls for improved staff consistency as a new GDUFA headache emerges for FDA.